Specialty preclinical CRO services

Explicyte Immuno-Oncology

We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.

In vitro screening
In vitro screening
Phenotypic screening & in vitro profiling in cancer cells co-cultured with PBMCs
Read more
In vivo studies
In vivo studies
in vivo proof-of-concept studies in validated syngeneic mouse tumor models
Read more
Biomarker analysis
Biomarker analysis
Immune biomarkers profiling in preclinical and clinical samples.
Read more

Cancer immunotherapy Latest News

  • In vivo syngeneic subcutaneous CT26 colon tumor model Shuttle session

    As in the previous shuttle session, Explicyte will plan a new shuttle on the CT26 tumor-bearing mouse model, which will be held in July. In this shuttle, our well-characterized syngeneic CT26 colon tumor-bearing mouse model will be used through standardized study protocols, for the evaluation of potential anti-tumor benefits from drug combinations with reference immune checkpoint inhibitors or chemotherapies....

  • In vitro immune cell-mediated killing

    In vitro immune cell killing assay to assess your immunomodulatory candidate compounds/antibodies for their ability to enhance the killing immune response towards tumor cells. By using live cell imaging platform, our sensitive and quantitative assay based on 96-well plate co-culture of human tumor cells...

  • Orthotopic mouse model of Glioblastoma

    Glioblastoma (GBM) is the most aggressive primary brain tumor. Despite multimodal treatment strategies with surgery, radiation therapy and chemotherapy, the prognosis of GBM patients remains dismal. GBM are characterized by a high immune cells infiltration including myeloid derived suppressor cells (MDSCs), microglia or regulatory T cells (Tregs), all of them contributing to the creation of an immunosuppressive micro-environment. ...

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4  monoclonal antibodies, anti PD1/PDL-1 antibody  therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France. However, we routinely serve clients in the US, EU, UK, Germany and Switzerland.